Asthma, Inflammation and G Protein-coupled Receptors (GPCR)
Primary Purpose
Asthma, COPD
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
spirometry
blood test
Sponsored by

About this trial
This is an interventional diagnostic trial for Asthma focused on measuring GPCR expression, transcriptomic, white blood cells, diagnostic, Control
Eligibility Criteria
Inclusion Criteria:
- Asthma group
- COPD group
- Control group
Exclusion Criteria:
- Patients with infection or inflammatory diseases
Sites / Locations
- Hospital
- Pascal Chanez
- University Hospital
- Antoine Magnan
- University Hospital, Strasbourg, France
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Other
Other
Other
Arm Label
A= Asthma
B= COPD
C= Control
Arm Description
Outcomes
Primary Outcome Measures
differential expression of GPCRs
Secondary Outcome Measures
Full Information
NCT ID
NCT00793676
First Posted
November 17, 2008
Last Updated
September 7, 2017
Sponsor
University Hospital, Strasbourg, France
Collaborators
National Research Agency, France
1. Study Identification
Unique Protocol Identification Number
NCT00793676
Brief Title
Asthma, Inflammation and G Protein-coupled Receptors (GPCR)
Official Title
G Protein Coupled Receptor (GPCR)Signature as Biomarker of Chronic Pulmonary Inflammatory Diseases and of Therapeutic Follow-up
Study Type
Interventional
2. Study Status
Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
September 2008 (undefined)
Primary Completion Date
September 2017 (Actual)
Study Completion Date
September 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Strasbourg, France
Collaborators
National Research Agency, France
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The G protein-coupled receptors (GPCRs) are a family of proteins expressed at the cell membrane. They are composed of 380 members involved in the important functions of the organism and are privileged therapeutic targets.Their expression is highly modulated depending on the metabolic state of the cells, in particular in pathological situations.our study proposes to determine whether GPCR expression modulation could be used as a biomarker, either prognostic or diagnostic, of treatments.To do so , the investigators will determine the expression profile of the 380 human GPCRs in human blood cell samples in two chronic inflammatory pulmonary diseases : asthma and COPD (chronic obstructive pulmonary disease ) . These have opposed inflammatory infiltrates : asthma is associated with eosinophil and Th2 lymphocyte infiltration whereas COPD shows neutrophils and macrophages within the airways with a Th1 lymphocytic population. The GPCR signature (transcriptomic) will be determined on total white blood cells as well as on isolated mono- and poly-nuclear populations obtained from healthy subjects and patients selected at the asthma or COPD consultation. The expression profiling analysis will reveal sub-groups of GPCRs whose expression is modified in disease. The specificity of the variation of expression of these biomarker sub-populations will be determined, by a study recruiting a hundred patients and controls per disease on this restraint number of genes. The outcomes of the project will lead to establish GPCR "identity cards" for these chronic inflammatory diseases, which might therefore be used as diagnostic or prognostic biomarkers to follow the evolution of a disease or the efficacy of a given treatment. In addition, detailed analysis of the identified GPCRs will lead to propose new therapeutic targets for inflammatory diseases. This study has therefore the objective of validating GPCRs as potential biomarkers for inflammatory diseases.
Detailed Description
Multicentre non-randomized
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma, COPD
Keywords
GPCR expression, transcriptomic, white blood cells, diagnostic, Control
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
205 (Actual)
8. Arms, Groups, and Interventions
Arm Title
A= Asthma
Arm Type
Other
Arm Title
B= COPD
Arm Type
Other
Arm Title
C= Control
Arm Type
Other
Intervention Type
Other
Intervention Name(s)
spirometry
Intervention Type
Other
Intervention Name(s)
blood test
Primary Outcome Measure Information:
Title
differential expression of GPCRs
Time Frame
1 day
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Asthma group
COPD group
Control group
Exclusion Criteria:
Patients with infection or inflammatory diseases
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Romain Kessler, MD
Organizational Affiliation
University Hospital, Strasbourg, France
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital
City
Colmar
ZIP/Postal Code
68024
Country
France
Facility Name
Pascal Chanez
City
Marseille
ZIP/Postal Code
13008
Country
France
Facility Name
University Hospital
City
Montpellier
ZIP/Postal Code
34295
Country
France
Facility Name
Antoine Magnan
City
Nantes
ZIP/Postal Code
44035
Country
France
Facility Name
University Hospital, Strasbourg, France
City
Strasbourg
ZIP/Postal Code
67000
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
28275176
Citation
Gras D, Martinez-Anton A, Bourdin A, Garulli C, de Senneville L, Vachier I, Vitte J, Chanez P. Human bronchial epithelium orchestrates dendritic cell activation in severe asthma. Eur Respir J. 2017 Mar 8;49(3):1602399. doi: 10.1183/13993003.02399-2016. Print 2017 Mar.
Results Reference
derived
Learn more about this trial
Asthma, Inflammation and G Protein-coupled Receptors (GPCR)
We'll reach out to this number within 24 hrs